Surging Cases Of Inflammatory Diseases To Boost Demand In Global Dexamethasone Market

Dexamethasone is an anti-inflammatory drug that is used to prevent or reduce the substance which is causing the inflammation. It is currently being used widely to treat several illnesses such as swelling, allergic disorders, adrenal problems, asthma, arthritis, bone marrow or blood problems, multiple sclerosis flare ups, skin conditions, and kidney problems. The drug is used in the treatment of COVID-19 pandemic, along with illnesses like breathing issues, psoriasis, lupus, arthritis, and colitis. It is sold in the form of brand name as well as generic drug, both sold at a cost-effective rate and in large amount by the manufacturers.

The exponential rise in demand for dexamethasone as a lifesaving medicine, especially COVID-19 patients because of an unexpected outburst is among the significant reasons heightening the development of the global dexamethasone market. Moreover, the vigorous demand in R&D activities and innovations is likewise adding to the surge in the global market in the forecast period. Besides, the outbreak of viral sickness episode and rising awareness concerning utilization of dexamethasone is also fueling the market. Moreover, the increasing death rate and approval for crisis utilization of dexamethasone for COVID-19 is expected to additionally uplift the market. The expansion in different inflammatory conditions will additionally speed up the development of the dexamethasone market. Nonetheless, the side-effects related with the utilization of dexamethasone are foreseen to block the development of the global dexamethasone market.

The global dexamethasone market is widely categorized into formulation, patient, application, and region. Based on formulation, the market is divided into solution for injection, tablet, liquid, and others. In terms of patient, the market is segregated into geriatric, pediatric, and adult. On the basis of application, the global dexamethasone market is bifurcated into respiratory ailments, COVID-19, immunosuppresent, and anti-inflammatory effects. The end-user segment is classified into online pharmacies, drug & pharmaceutical stores, clinics, and hospitals.

Geographically, North America is likely to register as a leading region in the global dexamethasone market within the forecast period. This is credited to rising cases of people suffering from COVID-19, along with prevalence of inflammatory ailments in the region. The second place is scored by Asia Pacific, owing to the outbreak of pandemic, presence of several leading players in the region, and increasing cases of viral diseases.

Cadila Healthcare Ltd., Dwarkesh Pharmaceuticals Private Limited, Wockhardt Ltd., Schwitz Biotech, Mapro Lifescience, Lexine Technochem Private Limited, Therawin Formulations, Acichem Laboratories, Shervotec Pharmaceuticals, Quality Nexgen Pharmaceuticals Pvt Ltd , Symbiotic Pharma, Kern Pharma SL, AuroMedics, Hikma, Fresenius Kabi, Mylan, American Regent, Somerset Therapeutics, Shanghai General Pharmaceutical, Chengdu Brilliant Pharmaceutical, Hunan Hansen Pharm, Cisen Pharmaceutical, Jiangsu Wuzhong Pharm, CSPC Group, and Guangzhou Baiyunshan Tianxin Pharmaceutical are some of the leading companies in the global dexamethasone market.

To cite, Sanofi recently announced the approval of Sarclisa (isatuximab) by U.S. Food and Drug Administration (USFDA), along with dexamethasone (Kd) and carfilzomib for treating the people with refractory or relapsed multiple myeloma (RRMM).

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *